2,2,15,15-tetramethylhexadecane-dioic acid | 210557-75-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,2,15,15-tetramethylhexadecane-dioic acid
• 英文别名: 2,2,15,15-tetramethylhexadecane-1,16-dioic acid；M16αα；2,2,15,15-tetramethylhexadecanedioic Acid
• CAS: 210557-75-8
• 化学式: C₂₀H₃₈O₄
• 分子量: 342.519
• InChiKey: LLFXYXPRAJLGTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  24
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
  申请人：——

  公开号：US20020049345A1

  公开（公告）日：2002-04-25

  The invention relates to carboxylic acids and derivatives thereof and pharmaceutical compound containing them. The active compounds are represented by the formula compound represented by formula I, wherin R 1 -R 4 each independently represents an unsubstituted or substituted hydrocarbyl or heterocyclyl radical, Q represents a diradical consisting of a linear chain of 11 to 18 carbon atoms, one or more of which may be replaced by heteroatoms, said chain being optionally substituted by inert substituents and one or more of said carbon or heteroatom chain members optionally forming part of a ring structure, and where one or both of de carboxyl groups can be substituted by an in vitro hydrolyzable physiologically acceptable substituent; with the proviso that: compounds wherein R 1 -R 4 each represents CH 3 and Q represents a linear chain of 14 carbons, are excluded; and compounds wherein Q represents a linear chain of carbon atoms one of which is replaced by oxygen or sulfur, are excluded. 1

  本发明涉及羧酸及其衍生物和含有它们的药物化合物。活性化合物由式I表示，其中R1-R4各自独立地表示未取代或取代的烃基或杂环基，Q表示由11到18个碳原子的线性链组成的双原子基团，其中可以有一个或多个被杂原子取代，该链可以被惰性取代基取代，并且该碳或杂原子链的一个或多个成员可以选择地构成环结构，其中一个或两个羧基可以被体外水解的生理可接受的取代基取代；但是具有以下特征：其中R1-R4表示CH3且Q表示14个碳原子的线性链的化合物被排除；以及Q表示碳原子链的一个原子被氧或硫替换的化合物被排除。
• Method of treating osteoarthritis
  申请人：——

  公开号：US20040048910A1

  公开（公告）日：2004-03-11

  This invention relates to combinations, compositions, and methods using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component for preventing or treating osteoarthritis, preventing or inhibiting cartilage damage, preventing or treating rheumatoid arthritis, improving joint function, alleviating pain, and the like in a patient in need thereof.

  本发明涉及使用或含有取代的二烷基醚、取代的芳基-烷基醚、取代的二烷基硫醚、取代的二烷基酮或取代的烷基化合物，或其药学上可接受的盐作为活性成分，用于预防或治疗骨关节炎、预防或抑制软骨损伤、预防或治疗类风湿关节炎、改善关节功能、缓解疼痛等方面的组合物、组成物和方法，适用于需要治疗的患者。
• Method of lowering CRP and reducing systemic inflammation
  申请人：——

  公开号：US20040167229A1

  公开（公告）日：2004-08-26

  Disclosed are methods of lowering plasma CRP levels, reducing systemic inflammation, and inhibiting proinflammatory cytokine induced CRP production by administering an effective amount of a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of the substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl or a pharmaceutical composition comprising a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl.

  本发明涉及通过给予有效量的取代二烷基醚、取代烷基、取代芳基-烷基、取代二烷基硫醚、取代二烷基酮、取代烷基或其药学上可接受的盐，以及包含取代二烷基醚、取代烷基、取代芳基-烷基、取代二烷基硫醚、取代二烷基酮、取代烷基的药物组合物，来降低血浆CRP水平，减少全身性炎症，并抑制促炎细胞因子诱导的CRP产生的方法。
• Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1
  申请人：Syndromex Ltd.

  公开号：US10512624B2

  公开（公告）日：2019-12-24

  Disclosed are methods of treatment of type 1 diabetes (T1D) in subjects under standard-of-care T1D treatment, by administration of substituted long-chain amphipathic dicarboxylic acids. Also disclosed are methods of reducing standard-of-care administered dose of insulin or an insulin analogue and/or obviating the need for administration of insulin or an insulin analogue in a T1D subject by administration of substituted long-chain amphipathic dicarboxylic acids.

  本发明公开了通过服用取代的长链两性二羧酸治疗接受标准治疗的 1 型糖尿病（T1D）受试者的方法。还公开了通过施用取代的长链两性二羧酸来减少 T1D 受试者胰岛素或胰岛素类似物的标准治疗剂量和/或避免施用胰岛素或胰岛素类似物的方法。
• Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates
  申请人：SYNDROMEX LTD.

  公开号：US11207285B2

  公开（公告）日：2021-12-28

  Disclosed are methods of treating of type 2 diabetes mellitus and associated conditions in humans by administering an α,α-substituted long-chain dicarboxylic acid. In some of the disclosed methods the α,α-substituted long-chain dicarboxylic acid is administered as add-on therapy to anti-diabetic Standard-of-Care treatment.

  公开了通过施用α,α-取代的长链二羧酸治疗人类2型糖尿病及相关疾病的方法。在某些已公开的方法中，α,α-取代的长链二羧酸是作为抗糖尿病标准治疗的附加疗法给药的。